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Abstract. Big longitudinal observational databases present the oppor-
tunity to extract new knowledge in a cost effective manner. Unfortu-
nately, the ability of these databases to be used for causal inference is
limited due to the passive way in which the data are collected resulting
in various forms of bias. In this paper we investigate a method that can
overcome these limitations and determine causal contrast set rules effi-
ciently from big data. In particular, we present a new methodology for
the purpose of identifying risk factors that increase a patients likelihood
of experiencing the known rare side effect of renal failure after ingest-
ing aminosalicylates. The results show that the methodology was able
to identify previously researched risk factors such as being prescribed
diuretics and highlighted that patients with a higher than average risk
of renal failure may be even more susceptible to experiencing it as a side
effect after ingesting aminosalicylates.
1 Introduction
Longitudinal observational data potentially hold a wealth of information, how-
ever we are currently limited in the ability to efficiently extract causal relation-
ships from this form of data due to bias and confounding [1]. In randomised
clinical trials confounding can be overcome by manipulating the variables and
mixing the potential confounders equally between the group given the drug and
the control group. Unfortunately, this is not possible for observational data as
the data are passively observed. As a consequence, spurious results are common
when analysing observational data due to the various forms of bias in the data.
In the medical field the gold standard for causal discovery are randomised clin-
ical trials [2]. However, these are costly and sometimes unethical [3]. If medical
longitudinal observational data could be successfully analysed and the results
used to complement randomised trials for causal discovery, then this would ad-
dress these issues. This would enable a greater understanding of various medical
mechanisms and enhance current knowledge.
Bayesian causal discovery techniques that learn complete causal models have
often been used to identify causal relationships in longitudinal observational
2data[4]. Due to scalability issues the recent focus has shifted towards constraint
based methods [5]. Although the constraint based methods have performed well
in some domains, they rely on numerous assumptions [6] that may not always
hold true and may still be inefficient for data with high volume and high variety.
A recent approach for identifying causal association rules included a two step
method, of firstly mining association rules and secondly implemented a cohort
study to filter out those that are likely to be causal. This was accomplished by
identifying controls that had the antecedent and matched specific attributes of
the cases. The odds ratio was then used as the filter, as only the rules with a
significant deviation between how often the consequence occurred for the cases
and controls were kept [7]. In this paper we attempt a similar approach for
identifying causal contrast sets but use logistic regression as a filter. Rather
than using the odds ratio, we use the p-values of the logistic regression variables
to indicate how significant having the antecedent is for the occurrence of the
consequence. As the logistic regression can consider covariates such as age, and
gender into the model, we can filter contrast set rules that are caused by observed
confounders.
In this paper we present a proof-of-concept candidate risk factor detection
algorithm based on causal contrast set mining. Causal contrast set mining is a
term we use to define the discovery of causal association rules that identify dif-
ferences between various groups. The algorithm firstly identifies interesting rules
consisting of sets of events that commonly precede a user specified event and then
investigates how often these interesting rules occur in general. Rules that occur
more often before the user specified event are then investigated via a logistic
regression model. This reduces age/gender confounding and highlights the most
interesting rules. We implement the methodology to a real word dataset. The
dataset we use is a UK general practice database containing complete medical
and drug prescription records for millions of patients within the UK. Our focus
is towards identifying risk factors for patients’ experiencing prescription drug
side effects for the drug family aminosalicylates (5-ASAs). These drugs are often
given to treat inflammatory bowel disease but are known to cause renal failure
with an incidence rate of 0.17 cases per 100 patients per year [8]. The purpose
of this research is to investigate a new technique for mining contrast set causal
relationships efficiently and evaluate its potential for identifying candidate risk
factors of patients experiencing side effects to prescribed medication.
2 Materials & Methods
2.1 The Health Improvement Network
The Health Improvement Network (THIN) database (www.thin-uk.com) is a
large longitudinal observational database containing medical records for millions
of patients within the UK. There are over 600 general practices within the UK
that are registered to the scheme consisting of over 3.5 million active patients.
For each patient within THIN, their demographics such as age, gender and lo-
cation are known, as well as their complete medical and therapy record histories
3during the period of time they are registered at a participating practice. The
suitability of this database for epidemiological study has been investigated and
the results show it is reasonably representative of the general UK population [9].
It is worth highlighting that the database does have some potential issues, such
as not containing over the counter prescriptions, only containing data that pa-
tients have told their doctors about and delays in the recording of medical event
into the database. A common problem with the database is historical event drop-
ping, when a patient moves general practices, it is common for the patient to
have historical illnesses/events recorded shortly after registering. To prevent this
biasing analyses, it is standard to exclude the first year of a patient’s records
after moving to a new general practice [10]. This preprocessing was implemented
in this study.
The READ code system is the coding system used within UK primary care
to record medical events [11]. Each READ code corresponds to a medical event
(e.g., a diagnosis, an administrative event, a laboratory result or a symptom).
The READ codes consist of 5 alphanumeric digits and have a hierarchal tree
structure based on the level of detail of the corresponding medical event being
recorded. The level of a READ code corresponds to how many non dot digits it
contains, for example the READ code ‘A10..’ is a level 3 READ code, whereas
the READ code ‘A....’ is a level 1 READ code. A level 2 READ code is the
child of a level 1 READ code if the READ codes have the same first digit. This
is generalised to a level n ∈ {2, 3, 4, 5} READ code being the child of the level
n− 1 READ code if the first n− 1 digits of both READ codes are the same. The
advantage of this hierarchal structure is that a child READ code represents a
more specific version of its parent READ code’s corresponding medical event. For
example, the READ code ‘A....’ corresponds to the description ‘Infection’ and
is the parent of the READ code ‘A1...’ corresponding to ‘Tuberculosis’, which is
the parent of the READ code ‘A11..’ corresponding to ‘Pulmonary tuberculosis’.
Prescriptions are recorded into THIN using a drug code and each prescription
also contains the drug’s British National Formula (BNF) code [12]. The BNF
code groups drugs into similar families. Each prescription can be linked to up to
three BNF codes.
2.2 Algorithms
Association rules mining Association rules mining [13] is a method for dis-
covering relations between variables in large databases. It was originally designed
to identify relationships between items that are commonly purchased together
(occur in the same shopping baskets). The relations are normally of the form
{antecedent events } → {consequence}, meaning that if we find all of the an-
tecedent events in a shopping basket, then we have a good chance of finding the
consequence. An example of an association rule is {milk, butter} → {bread},
which means shoppers that buy milk and butter are also likely to buy bread.
The search space for identifying association rules can be extremely large with
big datasets. Therefore it is common to restrict the search to only include rules
containing sets of items that appear frequently in baskets. This is accomplished
4by specifying a minimum support threshold, and only items/itemsets that occur
more often than the support are considered. These are referred to as frequent
itemsets.
Formally, let I = {i1, i2, ..., in} be a set of n items and t = X ⊂ I be a trans-
action containing a set of items. We denote the database by D = {t1, t2, ..., tm}.
This is a set of m transactions. The support of an itemset X is the proportion
of transactions within the database that contain X,
supp(X) = |{ti ∈ D|X ⊂ ti}|/m (1)
An itemset X is said to be frequent if its support is greater than a given threshold
supp(X) > ω, where ω is called the minimum support.
The confidence of an association rule X → Y is the fraction of baskets that
contain bothX and Y (supp(X∪Y )) divided by the number of baskets containing
X (supp(X)),
conf(X → Y ) = supp(X ∪ Y )/supp(X) (2)
this is similar to the conditional probability of Y given X . In general, the as-
sociation rules X → Y are identified such that the support and confidence of
X → Y are greater than the minimum support and confidence thresholds.
There are various methods for identifying contrast set rules, including dis-
covering emergent patterns by considering the ratio of two supports [14], using
a suitable search technique combined with statistical hypothesis testing [15] or
creatively using a classifier [16]. Emergent pattern discovery is suitable for sim-
ple problems that only require contrasting two groups. This is what we will do
to identify candidate risk factors, as we just need to compare the patients that
experienced the adverse drug reaction with those that did not.
Logistic Regression Logistic regression [17] is a method that expresses the
log odds of belonging to a class as a linear combination of the features,
ln(P (Y |X)/(1− P (Y |X))) = w0 +
∑
i
wiXi (3)
The parameters wi are found using maximum likelihood. This is re-arranged to
give the conditional probability of belonging to each class as,
P (Y = 0|X) =
exp(w0 +
∑
i
wiXi)
1 + exp(w0 +
∑
i
wiXi)
P (Y = 1|X) =
1
1 + exp(w0 +
∑
i
wiXi)
(4)
therefore, class 0 is chosen when exp(w0 +
∑
i
wiXi) > 1 and 1 is chosen other-
wise. The parameter wi and its standard error of the logistic regression tell us
how significant the ith feature, Xi, is in determining the class. In this paper we
use a significance level of 5%.
52.3 Methodology
The proposed candidate risk factor identification methodology consists of four
steps. The first step is creating two different databases based on whether a
patient who was prescribed a 5-ASA experienced renal failure or not. The second
step is to identify frequent itemsets for the patients who experience renal failure
after 5-ASAs and calculate whether these itemsets occur more often for these
patients than for the patients prescribed 5-ASAs in general. This identifies any
potential risk factors that are common (occur in more than 5% of the patients).
The third step is to identify whether these potential risk factors are a significant
influence on experiencing renal failure after a 5-ASA when accounting for age
and gender confounding. The final step is presenting the frequent itemsets that
occur more than in general for the patients who experience renal failure after a 5-
ASA ordered by the p-value indicating the significance of the itemset’s presence
in predicting the chance of renal failure after a 5-ASA.
Step 1: Partition Databases Similar to market baskets, patients medical
baskets can be constructed based on the records they have in the THIN database
and frequent itemset mining can be applied to find frequent medical events sets.
Due to the number of possible itemsets being very large, frequent itemset mining
is often restricted so that only interesting itemsets are discovered.
To generate association rules for the THIN database we consider the items to
be all the medical events and all the drugs recorded within the THIN database.
So the THIN items are I = {all the medical events and all the drugs} and a
transaction isX ⊂ I. Then we generated two databases from the THIN database:
D1 contains the itemsets of patients that took 5-ASA but did not suffer from
renal failure within a month and D2 contains the itemsets of patients that took
5-ASA and suffered from renal failure within a month. For each transaction,
tD1
i
∈ D1 or tD2
i
∈ D2, the transaction consists of all the items within the THIN
database that are recorded for the ith patient in the database.
For example, if a patient had renal failure recorded within a month of a 5-ASA
and only had the READ codes 681.., 8CB.., 9R8.., 246.. and H33..00 recorded
in THIN, then his corresponding transaction in D2 would be {681..,8CB..,9R8..,
246.., H33..}.
Step 2: Calculating Support Ratio In general the THIN data is sparse and
the majority of items have a low support. However, to identify risk factors for
renal failure after ingesting a 5-ASA we only need to investigate the itemsets
that are frequent in the patients that took 5-ASA and suffered from renal failure
(frequent itemsets in D2). Then we need to find which of these frequent itemsets
from D2 have a higher support than within D1, as this indicates itemsets that
are more common in the 5-ASA patients who experience renal failure compared
to all the 5-ASA patients. Therefore, we apply frequent itemset mining to the
database D2 with minimum supports of ω = 0.05 and for each frequent item we
also calculated its support in D1. We then calculate the support ratio for each
6frequent itemset X from D2,
suppRatio(X) = [|{ti ∈ D2|X ⊂ ti}|/m2]/[|{ti ∈ D1|X ⊂ ti}|/m1] (5)
where m1 and m2 are the number of patients that took 5-ASA but did not suffer
from renal failure and took 5-ASA and suffered from renal failure, respectively.
The value ω = 0.05 was chosen as this means that any identified risk factors
occur for at least 5% of the patients experiencing renal failure after 5-ASA.
Therefore we are identifying common risk factors, however this value can be
adjusted.
After applying the association rules, we will get a table containing the fre-
quent itemsets of D2 and their support in both D1 and D2. The rate of each fre-
quent itemset corresponds to the ratio of two support values (support(X,ASA→RF)
/ support(X,ASA→ ¬RF)), see Table 1. The itemsets with a suppRatio greater
Table 1. Example of how to calculate the suppRatio for each frequent itemset.
Itemset (X) Support(X,ASA→RF) Support(X,ASA→¬RF) suppRatio(X)
{G2...} 0.15903 0.056378 2.820757
{G3...} 0.080863 0.028041 2.883717
{6781.,G2...00} 0.067385 0.023302 2.891863
{D21z.} 0.067385 0.029588 2.277463
{65E..} 0.078167 0.036105 2.165022
...
than 1 are considered potential risk factors that will be further evaluated using
logistic regression.
Step 3: Logistic Regression We then applied logistic regression with the in-
dependent variables: presence of potential risk factor, presence of 5-ASA, age and
gender and dependant variable indicating renal failure. This identified whether
the potential risk factors are in fact significant risk factors for experiencing renal
failure after 5-ASAs when accounting for age/gender confounding.
To apply the logistic regression we needed to consider a set of cases (the
patience with renal failure recorded in THIN) and a set of controls (the patients
with no renal failure recorded in THIN). For each patient experiencing renal
failure we selected 5 controls who did not. Increasing the number of controls per
case is a technique that can increase the power of the analysis and 5 controls
per case were chosen as we have a large number of controls available but only a
limited number of cases. For each case, the age used in the logistic regression is
considered as the age when the case first suffered from renal failure in life. Each
control was selected by picking a random non-renal failure patient and a random
point in the time while the patient is active in THIN such that the age/gender
distributions of the cases and controls were the same.
7Table 2. Example of the data used for each logistic regression.
PatientId Age Gender X ASA RF
1 45 1 True True True
2 50 2 False True False
3 45 1 False True True
4 59 2 False True False
5 22 2 True False True
...
Then, for each potential risk factor frequent itemset identified in step 2 (each
X) we created the case/control data as displayed in Table 2, where the variable
X is True if the patient’s itemset up to their specified age contains X , the
variable ASA is True if the patient was prescribed a 5-ASA before the specified
age and RF is True if the patient has renal failure recorded in THIN and False
otherwise. The logistic regression with RF as the dependant variable was then
applied considering the independent variables: age, gender, X , and ASA. The
interaction between the ASA variable and the X variable was also included.
Step 4: Ranking The p-value of the interaction between the frequent itemset
and 5-ASA was calculated to evaluate whether the frequent itemset is a risk
factor of experiencing renal failure after 5-ASA. The smaller the p-value is, the
greater the confidence that the frequent itemset corresponds to a risk factor.
The p-value of each frequent itemset is extracted and listed in the result table.
The results are returned ordered by the p-values in ascending order. The final
Table 3. Example of the output of the methodology.
Itemset (X) P-value(Age) P-value(Gender) P-value(ASA*Rules)
{9N1O.} 8.25E-8 3.08E-1 2.78E-18
{G33..} 1.87E-8 2.06E-1 2.28E-44
...
output of the methodology is this ranked list of frequent itemsets as illustrated
in Table 3.
2.4 Software
We use SQL to manage the data and R [18] to perform the analysis. The package
arules [19] was used to identify the frequent itemsets.
83 Results & Discussion
Table 4: The results of the candidate risk factor identification for
the occurrence of renal failure after 5-ASA.
Description RFsupp noRFsupp suppRatio p-value Potential Link
(val ×10−2) (val ×10−2)
Hypertensive
disease
15.9 5.64 2.82 1.62× 10−30 Hypertension
Furosemide tabs 11.9 3.21 3.70 7.86× 10−30 Diuretics [20]
BP reading 8.63 2.16 3.99 1.69× 10−24 Hypertension
Co-proxamol tabs 28.3 17.4 1.63 1.16× 10−23 Pain
Rheumatoid
arthritis
24.5 14.1 1.74 1.3× 10−23 Arthritis
Blood pressure
reading
9.70 2.92 3.32 1.42× 10−23 Hypertension
Furosemide &
Co-proxamol tabs
6.74 1.38 4.89 3.07× 10−23 Diuretics &
Pain
Diabetes mellitus 8.36 2.14 3.91 8.22× 10−23 Diabetes
Influenza
inactivated split
virion vaccine
9.43 2.70 3.50 1.1× 10−22 Influenza vac-
cination
Co-proxamol tabs
& Hypertensive
disease
7.01 1.82 3.84 4.62× 10−21 Pain & Hyper-
tension
Pain 11.9 5.03 2.36 2.31× 10−18 Pain
Osteoarthritis 11.1 4.65 2.38 1.1× 10−17 Arthritis
Co-proxamol tabs
& Pain
7.82 2.70 2.89 4.41× 10−16 Pain
Ischaemic heart
disease
8.09 2.80 2.88 4.51× 10−16 Hypertension
Co-proxamol tabs
& Rheumatoid
arthritis
10.2 4.48 2.29 2.31× 10−15 Pain & Arthri-
tis
Health education
offered &
Hypertensive
disease
6.74 2.33 2.89 2.45× 10−14 Hypertension
Influenza
inactivated
surface antigen
vaccine
9.97 4.52 2.21 5× 10−14 Influenza vac-
cination
Atenolol tabs 10.2 4.68 2.19 5.4× 10−14 Hypertension
Screening-health
check
9.16 4.17 2.20 1.66× 10−13
9Amoxicillin caps
& Hypertensive
disease
6.20 2.21 2.80 4.02× 10−13 Antibiotic &
Hypertension
Essential
hypertension
12.9 7.58 1.71 2.59× 10−12 Hypertension
Pain &
Screening-general
6.47 2.47 2.62 5.03× 10−12 Pain
Influenza
vaccination
7.82 3.61 2.17 5.95× 10−12 Influenza vac-
cination
Arthritis 11.1 6.12 1.81 2.68× 10−11 Arthritis
Anaemia
unspecified
6.74 2.96 2.28 5.94× 10−11 Anaemia
Loperamide caps 7.28 3.42 2.13 1.27× 10−10 Dehydration
[20]
Cardiac disease
monitoring
7.01 3.11 2.25 1.79× 10−10 Hypertension
Amoxicillin caps
& Pain
6.20 2.63 2.36 1.85× 10−10 Antibiotic &
Pain
Paracetamol tabs 15.4 10.5 1.46 2.33× 10−10 Pain
Screening-general
& Rheumatoid
arthritis
7.28 3.46 2.10 4× 10−10 Arthritis
The top 30 antecedents that occur significantly more often for patients who
experience renal failure after ingesting a 5-ASA, ordered by the logistic regression
p-value, are presented in Table 4. The results suggest that some potential risk
factors for experiencing renal failure after ingesting a 5-ASA are hypertension,
diuretics, pain, arthritis, diabetes, influenza vaccination, anaemia, dehydration
and antibiotics.
The results identified some known risk factors. However, in general there
is little information about the risk factors making the evaluation difficult. This
highlights the importance of a new methodology for discovering risk factors. In a
previous study it was observed that diuretics and dehydration may be risk factors
[20]. The diuretic drug furosemide was ranked second by the methodology and
patients with a history of furosemide were 3.7 times more likely to experience
renal failure after 5-ASAs. We found that those with a history of co-proxamol
and furosemide were 4.89 times more likely to experience renal failure after 5-
ASAs. The drug loperamide was also identified as a risk factor by the method.
This drug is used to treat diarrhoea and may indicate that the patients who
experienced renal failure after loperamide and 5-ASAs were dehydrated.
Hypertension is a general risk factor for developing renal failure. Interestingly,
this research suggests that 5-ASAs increase hypertension suffering patients’ sus-
ceptibility to renal failure. Therefore 5-ASA may need to be prescribed more
carefully to patients who are already susceptible to renal failure. It is common
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for side effects to occur in patients that have a higher background risk of the
event, so this is not unexpected.
Some painkillers and drugs used to treat hypertension are known to cause
renal failure. The identification of pain and hypertension as risk factors may
indicate an interaction between these drugs and the 5-ASAs that results in the
side effect of renal failure. Therefore the methodology may highlight indirect risk
factors. This does highlight one limitation of this methodology, it is difficult to
identify whether the medical event or the drugs used to treat the medical event
may be risk factors. Additional work will be required to determine whether the
identified potential risk factor is a direct or indirect risk factor.
It is worth highlighting that this methodology cannot definitively determine
the risk factors of known adverse drug reactions. Any results obtained need to
be validated via formal epidemiological studies. However, this method can high-
light the most likely risk factors and can be considered to be a filter. Therefor
this methodology may lead to more efficient discovery of unknown risk factors
by identifying which candidate risk factors should be investigated further. Effec-
tively this methodology is an ADR risk factor filter.
In this paper we chose to use a minimum support of 0.05 as this ensured any
identified risk factors occurred for more than 5% of the patients who experienced
the side effect. This value may need to be adjusted based on the type of risk
factors of interest or based on how common the side effect being investigated is.
4 Conclusions
In this paper we have presented a proof-of-concept of a novel methodology for
identifying causal contrast set rules in big longitudinal observational data. The
methodology was able to identify known risk factors for patients experiencing
renal failure after ingesting a 5-ASA drug. However this methodology cannot
be considered to definitively identify risk factors. Rather, it acts as a filter for
highlighting the most interesting.
Potential areas of future work are developing a way to tune the minimum
support used to identify the frequent itemsets and applying the methodology to
a range of known prescription side effects to determine its robustness.
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